WO1994020512B1 - Analogues pour interactions specifiques oligosaccharide-proteine et utilisation desdits analogues - Google Patents

Analogues pour interactions specifiques oligosaccharide-proteine et utilisation desdits analogues

Info

Publication number
WO1994020512B1
WO1994020512B1 PCT/US1994/002051 US9402051W WO9420512B1 WO 1994020512 B1 WO1994020512 B1 WO 1994020512B1 US 9402051 W US9402051 W US 9402051W WO 9420512 B1 WO9420512 B1 WO 9420512B1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
analog
specific
sequence
isolated
Prior art date
Application number
PCT/US1994/002051
Other languages
English (en)
Other versions
WO1994020512A2 (fr
WO1994020512A3 (fr
Filing date
Publication date
Application filed filed Critical
Priority to EP94910755A priority Critical patent/EP0688327B1/fr
Priority to AU63532/94A priority patent/AU6353294A/en
Priority to DE69418322T priority patent/DE69418322D1/de
Publication of WO1994020512A2 publication Critical patent/WO1994020512A2/fr
Publication of WO1994020512A3 publication Critical patent/WO1994020512A3/fr
Publication of WO1994020512B1 publication Critical patent/WO1994020512B1/fr

Links

Abstract

La présente invention concerne (1) des procédés d'identification de séquences naturelles et synthétiques possédant une spécificité de liaison pour des protéines liant le glycane, y compris des protéines agissant en tant qu'effecteurs de l'activité biologique, (2) des compositions et procédés de production d'une séquence glycoaminoglycane à spécificité de liaison pour une protéine et des antagonistes de ligands capables de moduler la fonction d'effecteur desdits ligands, ainsi que des compositions thérapeutiques comportant lesdits antagonistes et (3) des compositions et procédés de production d'analogues de séquences de glycosaminoglycane à spécificité de liaison pour une protéine utiles en tant qu'agonistes et des compositions thérapeutiques comportant lesdits agonistes.
PCT/US1994/002051 1993-03-01 1994-02-28 Analogues pour interactions specifiques oligosaccharide-proteine et utilisation desdits analogues WO1994020512A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94910755A EP0688327B1 (fr) 1993-03-01 1994-02-28 Analogues d'interactions specifiques oligosaccharide-proteine et leur utilisations
AU63532/94A AU6353294A (en) 1993-03-01 1994-02-28 Analogs for specific oligosaccharide-protein interactions and uses therefor
DE69418322T DE69418322D1 (de) 1993-03-01 1994-02-28 Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2455893A 1993-03-01 1993-03-01
US024,558 1993-03-01

Publications (3)

Publication Number Publication Date
WO1994020512A2 WO1994020512A2 (fr) 1994-09-15
WO1994020512A3 WO1994020512A3 (fr) 1994-11-24
WO1994020512B1 true WO1994020512B1 (fr) 1995-01-05

Family

ID=21821208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002051 WO1994020512A2 (fr) 1993-03-01 1994-02-28 Analogues pour interactions specifiques oligosaccharide-proteine et utilisation desdits analogues

Country Status (7)

Country Link
US (1) US5795860A (fr)
EP (2) EP0900804A2 (fr)
AT (1) ATE179712T1 (fr)
AU (1) AU6353294A (fr)
CA (1) CA2157388C (fr)
DE (1) DE69418322D1 (fr)
WO (1) WO1994020512A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
EP1039883A4 (fr) 1996-07-09 2001-09-26 Keith A Crutcher Methodes de traitement de maladies liees a l'apolipoproteine e
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU4325499A (en) * 1998-06-01 1999-12-20 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9913415D0 (en) * 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US8314060B2 (en) * 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
WO2002020715A2 (fr) * 2000-09-05 2002-03-14 Biosight Ltd. Promedicaments peptidiques anticancereux conjugues
EP1455835A2 (fr) * 2001-12-13 2004-09-15 ISM Biopolymer Inc. Procede permettant de moduler la liberation de saccharides et utilisations dudit procede
DE10258770B4 (de) * 2001-12-18 2005-02-10 F. Hoffmann-La Roche Ag Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen
CH696701A5 (de) * 2001-12-18 2007-10-15 Hoffmann La Roche Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen.
GB0216861D0 (en) * 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
WO2004109282A1 (fr) * 2003-06-10 2004-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispositif electronique permettant de communiquer avec des cellules vivantes
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
EP0337327A1 (fr) * 1988-04-09 1989-10-18 Bioiberica, S.A. Procédé de préparation de fractions oligosaccharides par une dépolymérisation chimique réglée d'héparine
EP0361960A3 (fr) * 1988-09-29 1992-01-02 RANNEY, David F. Procédé et compositions pour la production d'images par résonance magnétique
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
EP0477195A1 (fr) * 1989-06-16 1992-04-01 The Upjohn Company Composes du type suramine et steroides angiostatiques inhibiteurs de l'angiogenese
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5116483A (en) * 1989-11-06 1992-05-26 Massachusetts Institute Of Technology Comb for affinity co-electrophoresis
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
AU7478191A (en) * 1990-03-05 1991-10-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Endogenous, suramin-induced, sulfated glycosaminoglycans as anti-cancer agents in humans
ES2060284T3 (es) * 1990-04-23 1994-11-16 Sanofi Elf Un procedimiento para la preparacion de un derivado de carbohidrato que comprende una unidad de trisacarido.
AU8007791A (en) * 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5166137A (en) * 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
MX9201801A (es) * 1991-04-16 1992-10-30 Seikagaku Kogyo Co Ltd Oligosacarido que tiene afinidad para el factor de desarrollo del fibroplasto y procedimiento para producirlo.
EP0509120B1 (fr) * 1991-04-18 1996-07-17 LABORATORI BALDACCI Spa Utilisation topique de glycosaminoglycanes pour la prévention et le traitement des maladies du tractus cervicovaginal
US5807982A (en) * 1991-04-29 1998-09-15 Cornell Research Foundation, Inc. Affinity purified heparin
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
WO1993007864A1 (fr) * 1991-10-23 1993-04-29 British Technology Group Ltd. Utilisation de suramine et de composes analogues comme agents contraceptifs
WO1993009800A1 (fr) * 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibiteurs de facteurs regulateurs cellulaires et procedes de prevention ou de reduction de la formation de cicatrices
AU679178B2 (en) * 1992-04-03 1997-06-26 La Jolla Cancer Research Foundation Decorin fragments and methods of inhibiting cell regulatory factors

Similar Documents

Publication Publication Date Title
WO1994020512B1 (fr) Analogues pour interactions specifiques oligosaccharide-proteine et utilisation desdits analogues
Tzeng et al. Platelet-derived growth factor promotes human peripheral monocyte activation
Burke et al. Synthesis of connective tissue macromolecules by smooth muscle
Baird et al. Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggests its identity with macrophage-derived growth factor
Chen et al. Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells.
Kiehlbauch et al. High resolution fractionation and characterization of ADP-ribose polymers
Brownell et al. Possible functions of mesenchyme cell-derived fibronectin during formation of basal lamina
CA2124583A1 (fr) Composes et compositions synthetiques a proprietes de fixation cellulaire ameliorees
Rathelot et al. Horse pancreatic lipase. Interaction with colipase from various species
JPH09136899A (ja) 天然のコロニー促進因子−１の精製
WO1992002822A1 (fr) Procedes d'identification d'inhibiteurs de convertase de cytokine
WO1994020512A3 (fr) Analogues pour interactions specifiques oligosaccharide-proteine et utilisation desdits analogues
Olson et al. Cell attachment activity of cementum proteins and mechanism of endotoxin inhibition
ES2186768T3 (es) Procedimiento para la purificacion de acidos nucleicos cortos.
LV10490A (lv) DNS seciba kas kode proteinus ar HUSI-tipa inhibitoru biologisko aktivitati mineto proteinu iegusanas biotehnologiskais panemiens farmaceitiskas kompozicijas kas satur minetos proteinus
Gitay-Goren et al. Transforming growth factor beta modulates gonadotropin receptor expression in porcine and rat granulosa cells differently
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
Heinegård et al. Common structures of the core proteins of interstitial proteoglycans
Festoff et al. In vitro studies of skeletal muscle membranes: Effects of denervation on the macromolecular components of cation transport in red and white skeletal muscle
Issandou et al. Diacylglycerols, unlike phorbol esters, do not induce homologous desensitization or down-regulation of protein kinase C in Swiss 3T3 cells
Akahane et al. Soluble Proteins from Fowl Feather Keratin: I. Fractionation and Properties
DE69729959D1 (de) Hybride zusammensetzungen für intrazellulaire verabreichung
Smith et al. Recombinant human interleukin-1α and recombinant human interleukin-1β stimulate cartilage matrix degradation and inhibit glycosaminoglycan synthesis
Lester et al. Human alpha-fetoprotein: immunosuppressive activity and microheterogeneity